
























# HIV Prevention Product Overview

Product	Yearly Dosage	Frequency, Volume, Delivery Site, Drug Class	Efficacy, Efficacy Date	Developer, Regulatory, Generics	LMIC Price PPPY
<b>Oral PrEP (TDF/FTC) (TDF/xTC) (F/TAF)</b> 		One pill <b>every day</b> ; event-driven dosing of 2-1-1 for cisgender men (TDF/FTC only)  TDF/FTC: Oral tablet - 200mg FTC, 300mg TDF  F/TAF: Oral tablet - 200mg FTC, 25mg TAF  Nucleoside reverse transcriptase inhibitor (NRTI)	<div>High </div> <div>High </div> <div><b>TDF/FTC - 2010</b> All populations (±90% with 7 doses/week); highly adherent-dependent  <b>F/TAF - 2011</b> Cisgender men &amp; TG women (±90% with 7 doses/week); highly adherent-dependent; PURPOSE 1 trial evaluating use in cisgender women, results expected 2027</div>	Gilead Sciences  >100 approvals WHO recommended in 2015  15+ suppliers globally	±\$40
<b>Dapivirine Vaginal Ring (DVR)</b> 		One ring <b>every month</b>  One 25mg dapivirine vaginal ring  Non-nucleoside reverse transcriptase inhibitor (NNRTI)	<div>Moderate </div> <div><b>DVR - 2016</b> Cisgender women (35% risk reduction in efficacy trials; 50%+ reduction with consistent use in Open Label Extension studies; highly adherent-dependent</div>	IPM / PopCouncil  11 approvals WHO recommended in 2021  MOU with Kiara in South Africa; license and timelines TBD	\$156
<b>Injectable Cabotegravir (CAB)</b> 	<div>Day 1 (Month 0)  Month 7 </div> <div>Month 1  Month 9 </div> <div>Month 3  Month 11 </div> <div>Month 5 </div>	First injection on day 1, second injection 1 month later, then <b>every 2 months</b>  One 3 mL intramuscular injection in gluteal muscle (buttocks)  Integrase strand transfer inhibitor (INSTI)	<div>Very High </div> <div><b>CAB - 2020</b> All populations (89% higher effectiveness in cisgender women and 66% in MSM and TG women, compared to oral PrEP)</div>	Viiv Healthcare  26 approvals WHO recommended in 2022  3 licenses via MPP, expected earliest market access in 2027	≅\$160 (set in GBP; USD subject to currency fluctuations)
<b>Injectable Lenacapavir (LEN)</b> 	<div>Day 1 (Month 0)*  + </div> <div>Day 2 (Month 0)* </div> <div>Month 6 </div> <div>Month 12  *Oral tablets taken only at time of initiation</div>	First injection and two oral tablets on day 1, two oral tablets on day 2, then injections <b>every 6 months</b>  Two 1.5 mL subcutaneous injections in abdomen and four 300mg lenacapavir tablets  Capsid inhibitor	<div>Very High </div> <div><b>LEN - 2024</b> All populations (100% efficacy in cisgender women, 96% reduction compared to background HIV incidence in cisgender men and TG and GNB people)</div>	Gilead Sciences  1 approval WHO recommended in 2025  6 direct licenses, expected earliest market access in 2027	TBD

LMIC = low- and middle-income country; PPPY = per person per year; TG = transgender; MSM = men who have sex with men; GNB = gender nonbinary